PL1633440T3 - Kompozycja farmaceutyczna zawierająca białka i/lub polipeptydy oraz cząstki koloidalne - Google Patents

Kompozycja farmaceutyczna zawierająca białka i/lub polipeptydy oraz cząstki koloidalne

Info

Publication number
PL1633440T3
PL1633440T3 PL04727664T PL04727664T PL1633440T3 PL 1633440 T3 PL1633440 T3 PL 1633440T3 PL 04727664 T PL04727664 T PL 04727664T PL 04727664 T PL04727664 T PL 04727664T PL 1633440 T3 PL1633440 T3 PL 1633440T3
Authority
PL
Poland
Prior art keywords
proteins
colloidal particles
polypeptides
polypeptide
protein
Prior art date
Application number
PL04727664T
Other languages
English (en)
Inventor
Moshe Baru
Lea Carmel-Goren
Original Assignee
Opperbas Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opperbas Holding Bv filed Critical Opperbas Holding Bv
Publication of PL1633440T3 publication Critical patent/PL1633440T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL04727664T 2003-04-15 2004-04-15 Kompozycja farmaceutyczna zawierająca białka i/lub polipeptydy oraz cząstki koloidalne PL1633440T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46270103P 2003-04-15 2003-04-15
EP04727664A EP1633440B1 (en) 2003-04-15 2004-04-15 Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles
PCT/IL2004/000327 WO2004091723A1 (en) 2003-04-15 2004-04-15 Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles

Publications (1)

Publication Number Publication Date
PL1633440T3 true PL1633440T3 (pl) 2008-12-31

Family

ID=33299976

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04727664T PL1633440T3 (pl) 2003-04-15 2004-04-15 Kompozycja farmaceutyczna zawierająca białka i/lub polipeptydy oraz cząstki koloidalne

Country Status (15)

Country Link
US (1) US20070167359A1 (pl)
EP (1) EP1633440B1 (pl)
JP (1) JP2006523683A (pl)
CN (1) CN1774281B (pl)
AT (1) ATE395101T1 (pl)
AU (1) AU2004229253B2 (pl)
BR (1) BRPI0409424B8 (pl)
CA (1) CA2522179C (pl)
DE (1) DE602004013769D1 (pl)
DK (1) DK1633440T3 (pl)
ES (1) ES2307009T3 (pl)
MX (1) MXPA05010926A (pl)
PL (1) PL1633440T3 (pl)
PT (1) PT1633440E (pl)
WO (1) WO2004091723A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2554161A1 (en) * 2011-08-02 2013-02-06 LFB Biotechnologies Pharmaceutical composition comprising factor VII encapsulated in micelles
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201518171D0 (en) * 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518170D0 (en) * 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518172D0 (en) * 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
CN115190883A (zh) * 2019-11-07 2022-10-14 伊利诺伊大学评议会 治疗脓毒症、动脉粥样硬化、血栓形成、中风、心脏病发作和炎症的肽和方法
CN115521603A (zh) * 2021-06-24 2022-12-27 复旦大学 一种可原位相转变形成凝胶的组合物及其用途
US20240058419A1 (en) * 2022-08-22 2024-02-22 Buddhist Tzu Chi Medical Foundation Method for treating optic neuropathy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
JP2989002B2 (ja) * 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
JPH0482839A (ja) * 1990-07-20 1992-03-16 Green Cross Corp:The 蛋白質類・脂質小体複合体
NZ260909A (en) * 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
US5874075A (en) * 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
IL112583A0 (en) * 1994-02-08 1995-05-26 Amgen Inc Oral delivery of chemically modified proteins
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
AU5773798A (en) * 1997-01-29 1998-08-18 Polymasc Pharmaceuticals Plc Pegylation process
AU747391B2 (en) * 1998-04-27 2002-05-16 Cantab Biopharmaceuticals Patents Limited Pharmaceutical composition comprising factor VIII and neutral liposomes
DE60026030T2 (de) * 1999-07-14 2006-08-10 Alza Corp., Mountain View Neutrales lipopolymer und liposomale zusammensetzungen daraus
MXPA02008023A (es) * 2000-02-18 2005-06-30 Yeda Res & Dev Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar.
WO2002086117A1 (en) * 2001-04-20 2002-10-31 The University Of Vermont Compositions and methods to control bleeding
IL162319A0 (en) * 2001-12-04 2005-11-20 Univ Ben Gurion Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting

Also Published As

Publication number Publication date
WO2004091723A1 (en) 2004-10-28
ES2307009T3 (es) 2008-11-16
JP2006523683A (ja) 2006-10-19
DE602004013769D1 (de) 2008-06-26
BRPI0409424B1 (pt) 2018-05-02
BRPI0409424B8 (pt) 2021-05-25
PT1633440E (pt) 2008-08-25
EP1633440A1 (en) 2006-03-15
US20070167359A1 (en) 2007-07-19
AU2004229253B2 (en) 2009-11-05
CN1774281A (zh) 2006-05-17
CA2522179A1 (en) 2004-10-28
AU2004229253A1 (en) 2004-10-28
BRPI0409424A (pt) 2006-04-25
ATE395101T1 (de) 2008-05-15
CA2522179C (en) 2012-02-14
MXPA05010926A (es) 2005-11-25
EP1633440B1 (en) 2008-05-14
CN1774281B (zh) 2010-10-13
DK1633440T3 (da) 2008-09-08

Similar Documents

Publication Publication Date Title
EP2476697A3 (en) Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
EP1778842B8 (en) Compositions and methods of use for mgd-csf in disease treatment
MXPA00010241A (es) Composicion farmaceutica que comprende el factor viii y liposomas neutrales..
CA2370289A1 (en) Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides
EP1845107A3 (en) RGD-enriched gelatine-like proteins with enhanced cell binding
EP1310558A3 (en) Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same
EP2267022A3 (en) KDR peptides and vaccines comprising the same
AUPP051497A0 (en) Antimicrobial peptides
BR0007597A (pt) Composição hipoalergênica contendo peptìdios tolerogênicos induzindo tolerância oral
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
AU2002212236A1 (en) An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof
MXPA05010926A (es) Composicion farmaceutica que comprende proteinas y/o polipeptidos y particulas coloidales.
EP0349342A3 (en) Polypeptides with cell-spreading activity
WO2001005810A3 (de) CYCLISCHE PEPTIDDERIVATE ALS INHIBITOREN DES INTEGRINS αvβ¿6?
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
EP2266535A3 (en) Controlled release compositions for interferon based on block polymers
CA2071757A1 (en) Implant compositions containing a biologically active protein, peptide or polypeptide
DE60329115D1 (de) Tumorantigenprotein und dessen verwendung
EP1790655A3 (en) Biologically active peptides
NZ591827A (en) Biologically active peptides comprising PTTKTYFPHF and their uses in the manufacture of a medicament for modulating immune reaction in a radiotherapy-induced immuno-compromised subject
ATE452903T1 (de) Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
WO2002083734A3 (en) Modified calcitonin
CA2163805A1 (en) Novel activating factor of leukocytes
WO2004032863A3 (en) Oral formulations for proteins and polypeptides
DE60223232D1 (de) Mucinpeptid mit immunstärkenden eigenschaften